Klemke, C. -D.; Hillen, U.; Grabbe, S.
Importance of cutaneous lymphomas in clinical practiceHAUTARZT. Bd. 68. H. 9. 2017 S. 680-681
Dietze-Schwonberg, Kirsten; Kautz-Neu, Kordula; Lorenz, Beate et al.
In cutaneous leishmaniasis, induction of retinoic acid in skin-derived Langerhans cells is not sufficient for induction of parasite persistence-mediating regulatory T cellsJOURNAL OF DERMATOLOGICAL SCIENCE. Bd. 87. H. 3. 2017 S. 307-309
Dietze-Schwonberg, Kirsten; Grewe, Beatrix; Brosch, Sven et al.
In silico prediction of Leishmania major-specific CD8(+) epitopesEXPERIMENTAL DERMATOLOGY. Bd. 26. H. 9. 2017 S. 838-840
Kaefer, Rudolf; Schrick, Katharina; Schmidtke, Lisa et al.
Inactivation of the KSRP gene modifies collagen antibody induced arthritisMOLECULAR IMMUNOLOGY. Bd. 87. 2017 S. 207-216
Loquai, Carmen; Schmidtmann, Irene; Garzarolli, Marlene et al.
Interactions from complementary and alternative medicine in patients with melanomaMELANOMA RESEARCH. Bd. 27. H. 3. 2017 S. 238-242
Cosgarea, I; Zimmer, L.; Weide, B. et al.
Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 PatientsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 16-17
Farkas, H.; Martinez-Saguer, I.; Bork, K. et al.
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiencyALLERGY. Bd. 72. H. 2. 2017 S. 300-313
Krebs, F.; Mitzel-Rink, H.; Jetter, A. et al.
Investigating immunosuppressive regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) in checkpoint inhibitor therapy of malignant melanomaEXPERIMENTAL DERMATOLOGY. Bd. 26. H. 3. 2017 S. E67-E67
Ascierto, Paolo A.; Del Vecchio, Michele; Robert, Caroline et al.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialLANCET ONCOLOGY. Bd. 18. H. 5. 2017 S. 611-622
Zimmer, Lisa; Apuri, Susmitha; Eroglu, Zeynep et al.
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaEUROPEAN JOURNAL OF CANCER. Bd. 75. 2017 S. 47-55